A method for estimating progression rates in Alzheimer disease.

BACKGROUND The ability to predict progression of disease in patients with Alzheimer disease (AD) would aid clinicians, improve the validation of biomarkers, and contribute to alternative study designs for AD therapies. OBJECTIVE To test a calculated rate of initial decline prior to the first physician visit (preprogression rate) for its ability to predict progression during subsequent follow-up. METHODS We calculated preprogression rates for 298 patients with probable or possible AD (using the criteria of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Associations (NINCDS-ADRDA) with a formula using expected Mini-Mental State Examination (MMSE) scores, scores at presentation, and a standardized estimate of duration. The patients are being followed up longitudinally in our Alzheimer Disease Research Center. The time to clinically meaningful deterioration, defined as an MMSE score drop of 5 or more points, was compared for patients stratified as slow, intermediate, and rapid progressors based on the preprogression rate. Cox regression analysis was used to examine the contribution of demographic variables (age, sex, ethnicity, and level of education), initial MMSE scores, estimated symptom duration, and the calculated preprogression rate to the time it took to reach the end point across the groups. RESULTS Both initial MMSE (hazard ratio, 0.95 (0.002); z = 4.19; P<.001) and the calculated preprogression rate (hazard ratio, 1.06 (0.019); z = 3.16; P =.002) were significant in determining time to clinically meaningful decline during longitudinal follow-up (Cox regression analysis). Slow, intermediate, and rapid progressors (based on preprogression rates) experienced significantly different time intervals to clinically meaningful deterioration, with the slow progressors taking the longest time, the intermediate progressors in the middle, and the rapid progressors reaching the end point first (log rank chi(2)(1) = 9.81, P =.002). CONCLUSION An easily calculable rate of early disease progression can classify patients as rapid, intermediate, or slow progressors with good predictive value, even at initial presentation.

[1]  K. Davis,et al.  A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. , 1994, The American journal of psychiatry.

[2]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[3]  M. Folstein,et al.  Population-based norms for the Mini-Mental State Examination by age and educational level. , 1993, JAMA.

[4]  G. van Belle,et al.  Reliability of estimates of changes in mental status test performance in senile dementia of the Alzheimer type. , 1990, Journal of clinical epidemiology.

[5]  A. Heyman,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1993, Neurology.

[6]  C. Pozzilli,et al.  Factors affecting course and survival in Alzheimer's disease. A 9-year longitudinal study. , 1994, Archives of neurology.

[7]  J A Yesavage,et al.  'How far' vs 'how fast' in Alzheimer's disease. The question revisited. , 1994, Archives of neurology.

[8]  M. Albert,et al.  Predicting time to nursing home care and death in individuals with Alzheimer disease. , 1997, JAMA.

[9]  J. Morris,et al.  Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease. , 1999, Archives of neurology.

[10]  J. Haxby,et al.  Individual trajectories of cognitive decline in patients with dementia of the Alzheimer type. , 1992, Journal of clinical and experimental neuropsychology.

[11]  M Schemper,et al.  New Residuals for Cox Regression and Their Application to Outlier Screening , 1999, Biometrics.

[12]  J. Yesavage,et al.  Identification of Fast and Slow Decliners in Alzheimer Disease: A Different Approach , 1995, Alzheimer disease and associated disorders.

[13]  L. Thal,et al.  Longitudinal evaluation of dementia of the Alzheimer type , 1990, Neurology.

[14]  M. Albert,et al.  Age at onset of Alzheimer's disease , 1994, Neurology.

[15]  L. Schneider,et al.  Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease. , 1994, Archives of neurology.